International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 2 | Views: 75 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Review Papers | Pharmacy | India | Volume 13 Issue 5, May 2024 | Rating: 5.1 / 10

A Review of Analytical Methods for Determination of Antidiabetic and Antihypertensive Drugs in Pharmaceuticals

Tadvi Nidhi | Krishna Kalsara | Umesh Upadhyay

Abstract: SGLT2 inhibitors are generally well-tolerated, with low rates of hypoglycemia. However, adverse effects such as genital mycotic infections and volume depletion-related events may occur, particularly in older adults. Beta-blockers reduce the workload of the heart by decreasing heart rate and contractility, which can help prevent myocardial ischemia and reduce the risk of further cardiac damage. The rational use of Dapagliflozin and Metoprolol in patients with heart failure is grounded in their distinct yet complementary mechanisms of action. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor known for its ability to reduce heart failure hospitalizations and cardiovascular events, particularly in patients with heart failure with reduced ejection fraction (HFrEF). Metoprolol, on the other hand, is a beta-blocker that has been a cornerstone in the treatment of heart failure for years, helping to reduce heart rate and improve cardiac function. Dapagliflozin and Metoprolol combination drug currently in phase 3. Our comprehensive literature survey has revealed an existing gap - there are no reported spectroscopic and chromatographic methods available for the precise determination of Dapagliflozin and Metoprolol, especially when used together. When used in combination, Dapagliflozin and Metoprolol offer a multifaceted approach to managing heart failure. Dapagliflozin addresses issues like fluid retention and cardiovascular risk, while Metoprolol helps to control heart rate and reduce the workload on the heart. This combination can potentially provide greater benefits to patients with heart failure, although its precise use and dosing should be determined by a healthcare professional based on the individual patient's medical history and condition. Clinical studies have shown promising results in the use of these medications together, and ongoing research continues to explore their effectiveness in improving outcomes for heart failure patients.

Keywords: Chromatography, dapagliflozin, metoprolol, analytical methods

Edition: Volume 13 Issue 5, May 2024,

Pages: 139 - 146

How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link

Verification Code will appear in 2 Seconds ... Wait